p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR),
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who consider risk-reducing
Li-Fraumeni syndrome: predicting cancer risk more precisely
The two MHH researchers Lucas John Müntnich and Professor Christian Kratz refer to the cluster analysis of the study,
Radiotherapy results in decreased time to second cancer in children with Li Fraumeni syndrome
UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome
High resolution clustering of TP53 variants into functional classes correlates with cancer risk among germline variant carriers and identifies different
Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome (“Toronto Protocol”)
In October 2016, the American Association for Cancer Research organized a meeting with international experts on Li-Fraumeni Syndrome (LFS) to
LFSA at the SU2C Summit: Progress Through Partnership
As I reflect on my recent trip to California to attend the Stand Up To Cancer Scientific (SU2C) Summit, it is a frigid
p53 Prophylactic Therapy for Cancer Prevention
Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations
New 2025 AACR Screening Guidelines for Li‑Fraumeni Syndrome Now Available
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association
Optimizing shared decision-making for risk-reducing mastectomy in women with Li–Fraumeni syndrome using patient-reported outcome measures
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with
Jenn Perry on WEEI for Jimmy Fund Telethon
LFSA founder Jenn Perry shares her family's LFS story and what motivates her to advocate for research and advancements to support those impacted by Li-Fraumeni
2011: Monograph on Li-Fraumeni Syndrome by David Malkin
Li-Fraumeni syndrome (LFS) is a genetic disorder linked to mutations in the p53 tumor suppressor gene, leading to a wide range of cancers. While p53
1988: A cancer family syndrome in twenty-four kindreds by Fred Li
Researchers analyzed families with a pattern of sarcomas, breast cancer, and other cancers occurring in young patients. They found that cancer developed in an autosomal
1987: Normal cytotoxic response of skin fibroblasts from patients with Li-Fraumeni familial cancer syndrome to DNA-damaging agents in vitro
Researchers tested cells from people with Li-Fraumeni Syndrome (LFS), a genetic condition that increases cancer risk, to see how they respond to DNA-damaging agents
Breast Cancer Screening Post-Mastectomy Study
You are being invited to participate in a questionnaire study being run by Dana-Farber Cancer Institute. This study consists of a one-time questionnaire and
Dollar For – Financial Assistance Webinar
Watch our latest webinar: Navigating Hospital Financial Assistance, presented by Dollar For. Hosted by the LFS Association, this webinar covers the essential topic of
